Abstract | PURPOSE OF REVIEW: With the advent of direct acting antiviral (DAA) therapy, the use of organs from hepatitis C virus infected (HCV+) donors is gaining more traction. In this review, we aim to: provide an overview of recent literature that supports the use of HCV+ organs, outline ongoing challenges to the use of these organs, and highlight the areas within this field where active investigation is ongoing. RECENT FINDINGS: The present review describes clinical outcomes related to the transplantation of both HCV+ nonviremic and viremic organs and the distinction between hepatic and nonhepatic transplants. It also discusses the current debate pertaining to the ideal treatment strategy for donor-derived HCV infection, that is pre-emptive therapy versus prophylaxis therapy. SUMMARY: Data suggest that the use of HCV+ organs is an effective and relatively well tolerated strategy to combat the organ scarcity. However, clinicians must be vigilant to a signal of increased inflammation as HCV+ organ transplantation becomes more universal. Recent studies suggest that shorter courses of DAA may sufficiently treat donor-derived HCV infection, however the best treatment approach to minimize risk, cost, and toxicity is still under investigation.
|
Authors | Katya Prakash, Saima Aslam |
Journal | Current opinion in organ transplantation
(Curr Opin Organ Transplant)
Vol. 25
Issue 4
Pg. 364-370
(08 2020)
ISSN: 1531-7013 [Electronic] United States |
PMID | 32520787
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Antiviral Agents
(therapeutic use)
- Hepacivirus
(drug effects, isolation & purification)
- Hepatitis C
(drug therapy, epidemiology, virology)
- Hepatitis C, Chronic
(drug therapy, epidemiology, virology)
- Humans
- Living Donors
(statistics & numerical data)
- Organ Transplantation
(methods, statistics & numerical data)
- Tissue and Organ Procurement
(methods)
- Viremia
(drug therapy, epidemiology, virology)
|